Sanofi Compounds to be Featured in 178 Abstracts at American Society of Hematology Annual Meeting
PR Newswire/Les Echos/
Sanofi Compounds to be Featured in 178 Abstracts at American Society of
Hematology Annual Meeting
- Scientific presentations include Sanofi JAK2 inhibitor, Clolar(r)/Evoltra(r),
Elitek(r), Mozobil(r) and Thymoglobuline(r) - Paris, France - December 3, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that new research spanning the company's marketed and investigational hematology products, including its late-stage selective JAK2 inhibitor, will be featured in 178 abstracts to be presented at the 2012 Annual Meeting of the American Society of Hematology in Atlanta, GA., December 8-11, 2012. "We have a strong commitment to developing treatment solutions for patients with difficult-to-treat blood cancers where there remains unmet medical need," said Debasish Roychowdhury, M.D., Senior Vice President and Head, Sanofi Oncology. "At this year's ASH, we unveil for the hematology community our selective JAK2 inhibitor, which we are investigating to fill existing treatment gaps in myelofibrosis. We look forward to the results of our Phase III trial in 2013." Abstracts to be presented at the meeting cover the latest research on Sanofi Oncology's marketed hematology products Clolar(r)/Evoltra(r), Elitek(r), Mozobil(r) and Thymoglobuline(r) as well as the novel, investigational selective JAK2 inhibitor (SAR302503). Sanofi Oncology's JAK2 inhibitor is in clinical development for the treatment of the three main types of myeloproliferative neoplasms: primary myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET). Key abstracts to be presented at ASH include: * A Phase II randomized dose-ranging study of the JAK2 selective inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera MF or post-essential throm bocythemia MF o Presenter: Moshe Talpaz, M.D., University of Michigan, USA o Poster #2837, Sunday December 9, 6:00pm - 8:00pm, Hall B1-B2, Building B * Analysis of the impact and burden of illness of polycythemia vera and essential thrombocythemia in the US o Presenter: Jyotsna Mehta, Sanofi, Cambridge, USA o Poster #2071; Saturday, December 8, 5:30pm - 7:30 pm, Hall B1-B2, Building B * Epidemiology of myelofibrosis, polycythemia vera and essential thrombocythemia in the European Union o Odile Moulard, Sanofi, Chilly Mazarin, France o Poster #1744, Saturday, December 8, 5:30 pm - 7:30 pm, Hall B1-B2, Building B * Epidemiology of myeloproliferative disorders in US - a real world analysis o Presenter: Ruben Mesa, M.D., Mayo Clinic Arizona, USA o Poster #2834; Sunday, December 9, 6:00pm - 8:00 pm, Hall B1-B2, Building B * Analysis of the impact and burden of illness of myelofibrosis in the US o Presenter: Hongwei Wang, Sanofi, Bridgewater, USA o Oral presentation #972; Tuesday, December 11, C211-C213, Building C About the Sanofi JAK2 Inhibitor JAK2 is a key enzyme for blood cell development. Mutations in JAK2 can lead to dysregulated JAK2 signaling and are thought to be a cause of MF. Patients with wild type JAK2 have also been shown to have persistent, dysregulated activation of the JAK2 signaling pathway, which may be caused by mutations in other proteins believed to drive the development of the disease. In early clinical studies, the Sanofi JAK2 inhibitor has shown activity in MF patients with both wild type and mutated (JAK2V617F) JAK2. About Clolar(r)/Evoltra(r) Approved in 49 countries, Clolar/Evoltra is for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior treatment options. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted. Clolar/Evoltra was the first chemotherapy in more than a decade approved specifically for children with ALL. About Mozobil(r) Approved in 42 countries, Mozobil rapidly and effectively increases the number of hematopoietic stem cells in the blood to prepare non-Hodgkin's lymphoma and multiple myeloma patients for an autologous hematopoietic stem cell transplant. Mozobil is used with another medication (G-CSF) to release hematopoietic stem cells from the bone marrow into the bloodstream by disrupting a bond that normally keeps stem cells anchored to the bone marrow. About Thymoglobuline(r) For the past 25 years outside of the US, and currently registered in 60 countries around the world for a variety of indications, Thymoglobuline has been an integral part of the immunosuppressive regimen for patients undergoing solid organ and allogeneic stem cell transplantation as well as a standard of care for patients with aplastic anemia who cannot undergo a stem cell transplantation. Thymoglobuline remains an appropriate first-line immunosuppressive therapy in the treatment of aplastic anemia based on its positive benefit/risk profile in those countries where no horse ATG is available. About Sanofi Oncology Based in Cambridge, Massachusetts, USA and Vitry, France, Sanofi Oncology is dedicated to translating science into effective therapeutics that address unmet medical needs for cancer and organ transplant patients. Starting with a deep understanding of the disease and the patient, Sanofi Oncology employs innovative approaches to drug discovery and clinical development, with the ultimate goal of bringing the right medicines to the right patients. We believe in the value of partnerships that combine our internal scientific expertise with that of industry and academic experts. Our commitment is to help patients live healthier and longer lives through novel science and innovative therapies, with a portfolio that includes 11 marketed products and more than 15 compounds in clinical development, including small molecules and biological agents. About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). Sanofi Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. # # # Contacts: Sanofi Media Relations Investor Relations Marisol Péron Sébastien Martel Tél. : + (33) 1 53 77 45 02 Tél. : + (33) 1 53 77 45 45 email@example.com firstname.lastname@example.org Lauren Musto Oncology Division Communications Tel: 1(617) 768-1993 ; Mobile 1(781) 572-1147 email@example.com
The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.
-0- Dec/03/2012 08:15 GMT